Insights powering innovation and value creation

Hand-picked Thought Leadership pieces in the Content Hub

Technology, Patents, and Sport
13 May 2026
VAR, goal-line tech, AI 3D player avatars, wearable trackers, the technology reshaping the 2026 World Cup and elite sport rests on a patent system that makes the R&D investment behind it worth taking.
Patents or Trade Secrets? When to Patent in Deep Tech Innovation
11 May 2026
Deep tech companies face unique IP challenges due to long development cycles, high upfront investment, and complex technologies that combine products and processes. This article explores when patents, trade secrets, or a combination of both offer the strongest protection. It explains how factors such as detectability, reverse engineering risk, disclosure to third parties, and employee mobility should shape IP strategy decisions. While patents are often best suited to externally visible or licensable technologies, trade secrets can be highly effective for internal processes and know‑how that deliver performance or cost advantages.
Is Your AI Conversation Privileged?
08 May 2026
Recent US court decisions have, for the first time, tested whether conversations with AI tools can be protected by legal privilege. In United States v. Heppner, a court held that documents generated by a defendant using a public AI platform were not protected by attorney‑client privilege, largely because the AI was not used within a lawyer‑directed relationship and the platform’s terms allowed data retention and disclosure. By contrast, in Warner v. Gilbarco, another court found that AI‑assisted materials created by a self‑represented litigant were protected under the work‑product doctrine, which has a more forgiving standard for waiver.
The evolution of nucleic acid sequencing and what it means for Genomics and IP
27 April 2026
This article outlines the evolution of nucleic acid sequencing, from early Sanger methods to next‑generation and long‑read technologies. The journey from deciphering individual DNA strands to sequencing entire genomes in hours represents one of biotechnology's most impressive transformations. The first human genome, completed through the Human Genome Project, took around 13 years to sequence and cost billions of dollars, whereas modern sequencing methods can now deliver a genome in hours for a few hundred dollars. For those interested in patents and life sciences, understanding the technical evolution of sequencing methods offers insights into how fundamental scientific advances translate into valuable patent portfolios.
World IP Day: The big ideas shaping IP's fastest-moving fields
24 April 2026
For World IP Day, we asked experts of EIP’s five growth areas: Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share a quick insight on innovation, IP trends, and what excites them about the future. Each responded to a single, focused question reflecting the role their team plays across EIP.
Thinking about IP from day one: strategic considerations for deep tech startups
08 April 2026
For deep tech startups, intellectual property decisions often come too late or cost too much too soon. This article explores why IP strategy should be considered from day one, even if formal protection comes later. It outlines how founders can decide what to patent, when trade secrets may be more appropriate, and how detectability, enforceability and cost should shape early choices. With a focus on practicality and commercial alignment, it also looks at how newer, AI‑assisted approaches can help startups take a more cost‑effective and flexible approach to building meaningful IP protection.
National offices report increases in national patent applications throughout Europe: Is the EPO no longer “killing” the national offices?
27 March 2026
National patent offices across Europe have reported a marked increase in patent filings in 2025, breaking with a long‑standing downward trend. Data from Germany, France, Italy, Sweden, Austria, Spain and Norway point to growing activity driven by digital technologies, electrification and increased university participation. At the same time, offices report a rise in self‑drafted and AI‑assisted applications, which may lower barriers to entry but also raise concerns about application quality and examination efficiency.
Make your bio(pharma) IP investment ready
22 March 2026
This recap of our LinkedIn Live series focuses on helping (bio)pharma businesses make their IP investment‑ready. Across three sessions, experts will discuss building resilient IP portfolios, making strategic IP decisions ahead of funding rounds, and what the evolving 2026 (bio)pharma landscape means for long‑term IP strategy.
Are professional guidelines making Patent Attorneys too cautious on AI?
19 February 2026
As AI use accelerates in patent practice, many European patent attorneys remain cautious due to professional AI guidelines from the epi. This article argues those guidelines are not a barrier, but a baseline for responsible use.
Provisional Agreement Reached on the EU Pharma Package: Takeaways for Pharmaceutical Companies
17 February 2026
The EU’s new Pharma Package will overhaul regulatory exclusivity, orphan drug incentives, antimicrobial innovation, and generic entry pathways, reducing standard protection periods while introducing new rewards like transferable exclusivity vouchers.
Beyond CRISPR: Precision to Platform
23 January 2026
Gene editing is entering a new phase, moving beyond CRISPR-Cas9’s breakthrough but costly, bespoke therapies toward more precise and scalable platforms. While CRISPR-based treatments like Casgevy have proven clinical success, they remain expensive and entangled in ongoing patent disputes over foundational IP. Next-generation tools such as base editing and prime editing avoid double-strand DNA breaks, enabling more accurate corrections and broader therapeutic potential. The field’s focus is now shifting to disease-agnostic platforms that can be adapted across many conditions, improving access and efficiency.
INTA 2026 Essentials: Where to stay, what to see and what to do
03 June 2026
Discover the INTA 2026 Essentials! This comprehensive guide will help you navigate your stay, showcasing the best accommodations, must-see attractions, and exciting activities to enjoy during your visit.
Real Conversations, Real Innovation
EIP Talks Logo

The Latest Episodes of EIP Talks in the Content Hub

In this episode of EIP Talks, Mark Lubbock and Ellen Keenan O'Malley, solicitors at EIP, explore the full lifecycle of intellectual property, from the initial spark of innovation to the commercialisation of ideas. They share practical insights into how we support clients through the challenges of protecting, developing and monetising IP.The conversation covers how clients typically engage with us, the importance of identifying and securing various forms of IP, and the legal strategies needed to navigate collaborations, ownership, and licensing. It also highlights the significance of well-drafted contracts, website compliance and investor readiness. Whether you're launching a new product, entering a partnership, or preparing for investment, this episode offers valuable guidance on building a strong IP foundation and turning innovation into commercial success.

In this episode of EIP Talks, our panel features four experienced paralegals: Lucy Jones (Head of Client Services at EIP), Lisa Dawn Gentry, Sarah Devereux, and Sofia Jernberg. Together, they bring decades of experience from the UK, US, and Sweden, and share their diverse journeys into the world of intellectual property. The discussion centres on the evolving role of the paralegal in patent portfolio management. The team explores how the profession has shifted from being primarily attorney-directed to paralegals taking a more proactive, client-facing, and autonomous role. They discuss the impact of new certifications, such as the European Patent Administrator Certification (EPAC), and how these qualifications have boosted confidence, knowledge, and client trust.

Hosted by Joshua Rozenberg, we bring you the inside story from the team behind the landmark Optis v Apple judgment—now the highest-value court-determined SEP license on record.Hear directly from Gary Moss, Chairman at EIP, Andy Sharples, Head of Litigation at EIP, and Arty Rajendra, Head of IP Disputes at Osborne Clarke, as they walk us through the issues which the case presented, the challenges, and the significance of the Court of Appeal’s decision to increase Apple’s license fee from $63.7 to over $700 million.We explore what this means for FRAND litigation, the future of SEP enforcement in the UK and how this ruling could impact global licensing dynamics.

Celebrating 3 Years of EIP Sweden
We're delighted to invite you to celebrate three years of EIP in Sweden — a journey of growth, collaboration, and bold ideas. To mark this milestone and the opening of our new Stockholm office, we're...
Codiphy Presents: Never Mind the Broligarchs - how the UK can emerge victorious in AI
The tech bros are selling their vision of a future with AI. But should the UK buy it, or is there another way? Join us for an evening of food, drinks, and lively discussion with industry experts.
Innovating for Investment: Harnessing Innovation and IP to Drive Growth
We are excited to invite you to an exclusive event designed for decision-makers in deep tech. This event will explore how innovation and IP can help start-ups grow and secure investment, focusing on...

Guides

The UPC Review
Decisions that shaped the Court's second full year, in one place.
INTA 2026: Your Guide to Our Events, Insights and Team
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.